NCT06446232 Influenza Vaccine Effectiveness in Among Young Children in Taiwan
| NCT ID | NCT06446232 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Influenza Vaccine Allergy |
| Study Type | OBSERVATIONAL |
| Enrollment | 1 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1 participants in total. It began in 2023-09-01 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project uses questionnaires to statistically analyze whether influenza vaccination is protective for young children.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of influenza by Flu A+B rapid antigen test * Known vaccination status Exclusion Criteria: * Unknown vaccination status
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06446232 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 18 Years, studying Influenza Vaccine Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06446232 currently recruiting?
Yes, NCT06446232 is actively recruiting participants. Contact the research team at u8809032@gmail.com for enrollment information.
Where is the NCT06446232 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06446232 clinical trial?
NCT06446232 is sponsored by National Taiwan University Hospital. The trial plans to enroll 1 participants.